{"title":"Intermediate-term follow-up and analysis of related factors associated with urinary incontinence and overactive bladder after laparoscopic radical prostatectomy-A multicenter cross-sectional study in China.","authors":"Le Shu, Dafei Weng, Yue Chen, Luwei Xu, Yiran Wang, Ziyang Liu, Gefei Chen, Ziwen Guo, Yanyan Feng, Huixing Pan, Peng Xue, Zhongqing Wei, Min Gu, Xiaobing Niu, Liucheng Ding","doi":"10.1097/CU9.0000000000000278","DOIUrl":"10.1097/CU9.0000000000000278","url":null,"abstract":"<p><strong>Purpose: </strong>The aim of this study was to evaluate the incidence of urinary incontinence (UI) and overactive bladder (OAB) in prostate cancer patients 12 months after laparoscopic radical prostatectomy (LRP), through a multicenter follow-up. Additionally, the study sought to analyze the association between potential risk factors and the occurrence of these complications.</p><p><strong>Methods: </strong>This retrospective study included 382 patients who underwent LRP across 9 institutions in Jiangsu Province, China, between January 2019 and March 2020. Clinical data, including the Overactive Bladder Symptom Score, the International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form, magnetic resonance imaging findings, and the number of pads used, were collected 12 months postoperatively to assess the incidence of UI and OAB. Univariate and multivariate analyses were conducted to identify factors associated with UI and bladder overactivity at the 12-month follow-up.</p><p><strong>Results: </strong>Among the 382 patients included in the analysis, 135 (35.3%) patients remained affected by UI 12 months after LRP. Multivariate statistical analysis identified membranous urethral length (MUL), body mass index (BMI), and age as significant predictors of UI at the 12 - month postoperative mark. Additionally, 139 (36.4%) patients reported the presence of overactive bladder (OAB) 12 months post - operation. UI and OAB were found to be risk factors for each other.</p><p><strong>Conclusions: </strong>In our multicenter retrospective study, the prevalence of UI and OAB 12 months after LRP was significantly higher than previously reported in the literature. Age, BMI, and MUL were found to be associated with postoperative UI. Notably, preoperative MUL served as a protective factor against UI at 12 months post-surgery, while UI and OAB were identified as mutual risk factors. These findings underscore the importance of preventing post-prostatectomy UI to mitigate or avoid the occurrence of postoperative OAB. It should be noted that the loss-to-follow-up rate in this study was 39.7%, which may limit the interpretation and generalizability of the results.</p>","PeriodicalId":39147,"journal":{"name":"Current Urology","volume":"20 3","pages":"180-184"},"PeriodicalIF":2.0,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13068483/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147677504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Robot-assisted urological tumor surgery using the MP1000 system: A prospective, single-center, single-arm clinical study.","authors":"Mingxin Diao, Wenzhi Gao, Kunlin Yang, Yaming Gu, Zhihua Li, Xinfei Li, Zihui Gao, Xuesong Li, Zheng Zhang","doi":"10.1097/CU9.0000000000000311","DOIUrl":"10.1097/CU9.0000000000000311","url":null,"abstract":"<p><strong>Objectives: </strong>This study is aimed to evaluate the safety and efficacy of the MP1000 robotic system in urological tumor surgery.</p><p><strong>Materials and methods: </strong>This prospective, single-center, single-arm clinical study evaluated data from urological tumor surgeries between June 2023 and December 2023. Patient demographics and perioperative outcomes were prospectively collected, and postoperative complications and success rates were analyzed. Ergonomics were assessed using the National Aeronautics and Space Administration Task Load Index.</p><p><strong>Results: </strong>A total of 28 patients underwent surgery during the study period. All procedures were successfully completed without conversion to standard laparoscopic or open surgery. All cases had negative surgical margins postoperatively, and no recurrences were observed within 3 months. The median glomerular filtration rate (GFR) at the third month after partial nephrectomy was 87.4 mL/min/1.73 m<sup>2</sup> (range, 55.64-124.33 mL/min/1.73 m<sup>2</sup>). The median GFR at the third month after nephroureterectomy was 65.52 mL/min/1.73 m<sup>2</sup> (range, 65.52-98.12 mL/min/1.73 m<sup>2</sup>). The GFR at the third month after radical nephrectomy was 57.22 mL/min/1.73 m<sup>2</sup>. The median prostate-specific antigen level for patients after radical prostatectomy was 0.01 ng/mL (range, 0-0.03 ng/mL) at 3 months. The short-term surgical success rate was 100%. Surgeons reported high comfort levels, with an overall National Aeronautics and Space Administration Task Load Index score of 12.89 ± 7.14.</p><p><strong>Conclusions: </strong>Based on our single-center experience, the MP1000 system demonstrated promising safety and efficacy in a variety of urological tumor surgeries.</p>","PeriodicalId":39147,"journal":{"name":"Current Urology","volume":"20 3","pages":"185-191"},"PeriodicalIF":2.0,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13068480/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147677499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Current UrologyPub Date : 2026-03-01Epub Date: 2025-10-02DOI: 10.1097/CU9.0000000000000308
Kirolos Eskandar
{"title":"The role of uropathogenic <i>Escherichia coli</i> biofilms in antibiotic-resistant urinary tract infections: Nanoparticle-based, phage therapy, and quorum-sensing inhibitor approaches.","authors":"Kirolos Eskandar","doi":"10.1097/CU9.0000000000000308","DOIUrl":"10.1097/CU9.0000000000000308","url":null,"abstract":"<p><strong>Background: </strong>Urinary tract infections (UTIs) caused by uropathogenic <i>E. coli</i> (UPEC) pose a global health challenge, largely due to UPEC biofilms that drive persistent infections and antibiotic resistance.</p><p><strong>Materials and methods: </strong>To explore the role of UPEC biofilms in antibiotic-resistant UTIs and summarize emerging therapeutic strategies, this study conducted a systematic review adhering to PRISMA guidelines and registered in PROSPERO (CRD420251040212). A structured search of PubMed, Google Scholar, Scopus, and Web of Science identified English-language studies published up to 2024, with 57 eligible studies selected after three-stage screening and analyzed via thematic synthesis.</p><p><strong>Results: </strong>This study explored UPEC biofilms enhance resistance through extracellular matrix barriers, persister cell formation, efflux pump upregulation, and horizontal gene transfer; emerging therapies including bacteriophage therapy, quorum-sensing inhibitors, and nanoparticle-based drug delivery effectively target biofilms by penetration, signaling disruption, and improved drug efficacy. Additional approaches such as antibiofilm peptides, probiotics, and immunotherapy also demonstrate potential.</p><p><strong>Conclusions: </strong>The UPEC biofilms are key to chronic UTIs, and novel targeted therapies offer promising solutions, but clinical validation, regulatory hurdles, and combination therapy optimization are critical for translation to clinical practice.</p>","PeriodicalId":39147,"journal":{"name":"Current Urology","volume":"20 2","pages":"82-88"},"PeriodicalIF":1.3,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12885708/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146158652","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Current UrologyPub Date : 2026-03-01Epub Date: 2026-02-03DOI: 10.1097/CU9.0000000000000319
{"title":"A Chinese expert consensus on prostate-pelvic syndrome.","authors":"","doi":"10.1097/CU9.0000000000000319","DOIUrl":"10.1097/CU9.0000000000000319","url":null,"abstract":"","PeriodicalId":39147,"journal":{"name":"Current Urology","volume":"20 2","pages":"61-68"},"PeriodicalIF":1.3,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12885677/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146158607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Current UrologyPub Date : 2026-03-01Epub Date: 2026-02-03DOI: 10.1097/CU9.0000000000000322
Daniele Bianchi, Enrico Finazzi Agrò
{"title":"Editorial comment to: Effectiveness of simultaneous electroacupuncture stimulation on the tibial and ilioinguinal-iliohypogastric nerves in the treatment of refractory overactive bladder syndrome in women.","authors":"Daniele Bianchi, Enrico Finazzi Agrò","doi":"10.1097/CU9.0000000000000322","DOIUrl":"10.1097/CU9.0000000000000322","url":null,"abstract":"","PeriodicalId":39147,"journal":{"name":"Current Urology","volume":"20 2","pages":"99-100"},"PeriodicalIF":2.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12885727/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146158554","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Current UrologyPub Date : 2026-03-01Epub Date: 2025-12-16DOI: 10.1097/CU9.0000000000000320
Sergey Kravchick, Daniel Shulman, Julia G Fitzgerald, Robert M Moldwin, Louis R Kavoussi, Sijo J Parekattil, Gennady Bratslavsky
{"title":"A simplified algorithm for management of CP/CPPS and associated entities: A summary table for general urologists.","authors":"Sergey Kravchick, Daniel Shulman, Julia G Fitzgerald, Robert M Moldwin, Louis R Kavoussi, Sijo J Parekattil, Gennady Bratslavsky","doi":"10.1097/CU9.0000000000000320","DOIUrl":"10.1097/CU9.0000000000000320","url":null,"abstract":"<p><strong>Background: </strong>Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) accounts for 25% urology clinic visits. Due to significant overlap with other conditions, CP/CPPS is frequently misdiagnosed and inadequately managed. Therefore, we provided a simplified diagnostic and treatment approach to CP/CPPS by subdividing it into distinct subcategories.</p><p><strong>Materials and methods: </strong>We systematically reviewed the published literature about CP/CPPS and its \"associated entities\", including interstitial cystitis/bladder pain syndrome, chronic bacterial vesiculitis, symptomatic prostate calcification, pudendal neuropathy, male accessory gland Inflammation, and Chlamydia trachomatis infection. We applied the UPOINTS system to differentiate CP/CPPS phenotypes, using male accessory gland inflammation solely to flag potential inflammatory-pelvic pain overlap.</p><p><strong>Results: </strong>The review yielded an evidence base of 140 articles pertaining to CP/CPPS treatment antibiotics, α-blockers, anti-inflammatory drugs, phytotherapeutics, neuromodulators, physical therapy, local blocks, injections, and minimal invasive treatments. CP/CPPS, interstitial cystitis/bladder pain syndrome, chronic bacterial vesiculitis, symptomatic prostate calcification, pudendal neuropathy, and C trachomatis infection, and developed type-specific, step-by-step diagnostic and therapeutic algorithms. The proposed treatment model includes physiotherapy, minimally invasive options, and innovative interventions.</p><p><strong>Conclusions: </strong>Dividing CP/CPPS into 6 distinct subtypes offers clinicians more targeted guidance when selecting appropriate diagnostic tools and therapeutic interventions. Sperm analysis is recommended for patients with a history of infertility, painful ejaculation, or hematospermia, whereas pyospermia warrants investigation using semen cultures, polymerase chain reaction testing, and transrectal ultrasound. Ct-infection should be ruled out in young patients with prostatitis-like symptoms, burning micturition, \"penile tip irritation,\" and a thick urethral discharge. Patients over 50 years of age who have failed conventional therapy may require cystoscopy. Transrectal ultrasound can help rule out clustered prostatic calcifications, especially in older, overweight patients with a persistently elevated International Prostate Symptom Score and an increased white blood cell count in postprostatic massage urine. This approach is recommended for guiding CP/CPPS treatment.</p>","PeriodicalId":39147,"journal":{"name":"Current Urology","volume":"20 2","pages":"69-81"},"PeriodicalIF":1.3,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12885674/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146158535","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Current UrologyPub Date : 2026-03-01Epub Date: 2026-02-03DOI: 10.1097/CU9.0000000000000327
Paolo Casale, Rodolfo Hurle, Nicolò M Buffi, Giovanni Lughezzani, Alberto Saita, Vittorio Fasulo, Marco Paciotti, Alessio Benetti, Roberto Peschechera, Luisa Pasini, Silvia Zandegiacomo, Paola Arena, Alessandro Uleri, Massimo Lazzeri
{"title":"Efficacy of early intravesical instillation of hyaluronic acid after transurethral resection of non-muscle-invasive bladder cancers: An open-label, prospective, single-center, randomized, controlled and parallel-group pilot study.","authors":"Paolo Casale, Rodolfo Hurle, Nicolò M Buffi, Giovanni Lughezzani, Alberto Saita, Vittorio Fasulo, Marco Paciotti, Alessio Benetti, Roberto Peschechera, Luisa Pasini, Silvia Zandegiacomo, Paola Arena, Alessandro Uleri, Massimo Lazzeri","doi":"10.1097/CU9.0000000000000327","DOIUrl":"10.1097/CU9.0000000000000327","url":null,"abstract":"<p><strong>Background: </strong>Lower urinary tract symptoms (LUTS) and pain are clinically relevant problems after transurethral resection (TURBT) of nonmuscle-invasive bladder cancer. Although intravesical instillation of hyaluronic acid has already been proven to be a valid treatment for storage LUTS and pain in patients with inflammatory bladder syndrome, its efficacy in patients who undergo TURBT is unknown. This study aimed to present the results of a prospective, randomized, controlled, clinical pilot study on the safety and clinical performance of HydealCyst (Fidia Farmaceutici S.p.A., Italy), a device formulated to provide progressive, long-lasting intravesical release of hyaluronic acid.</p><p><strong>Materials and methods: </strong>Adults diagnosed with nonmuscle-invasive bladder cancer and scheduled for TURBT were included and underwent 4 visits up to 25 days after TURBT. Of the 47 patients who completed the investigation, 25 participants received 2 postoperative intravesical instillations with HydealCyst. The efficacy of HydealCyst on storage LUTS, pain, urinary symptoms, and patients' quality of life was evaluated using validated questionnaires.</p><p><strong>Results: </strong>Although the overall LUTS were similar in the 2 experimental groups, lower micturition frequency and fewer daytime micturitions were observed in patients treated with HydealCyst. These patients also showed a significant reduction in pain (<i>p</i> = 0.03) 3 days after catheter removal and better quality of life at the end of the study. The device was well tolerated, with no treatment-emergent adverse events of severe intensity.</p><p><strong>Conclusion: </strong>The results from this pilot study indicate a clinically meaningful improvement of symptoms after 2 instillations of HydealCyst, supporting this intervention as a potentially effective treatment for LUTS and pain after TURBT.</p>","PeriodicalId":39147,"journal":{"name":"Current Urology","volume":"20 2","pages":"117-124"},"PeriodicalIF":1.3,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12885686/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146158617","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Current UrologyPub Date : 2026-03-01Epub Date: 2026-02-03DOI: 10.1097/CU9.0000000000000329
Niklas Harland, Lea E Reitnauer, Bastian Amend, Veronika Bahlinger, Jörg Hennenlotter, Arnulf Stenzl, Wilhelm K Aicher, Simon Walz
{"title":"Significant differences in CD276 (B7H3) expression between female and male bladder cancer tissue samples: An exploratory study.","authors":"Niklas Harland, Lea E Reitnauer, Bastian Amend, Veronika Bahlinger, Jörg Hennenlotter, Arnulf Stenzl, Wilhelm K Aicher, Simon Walz","doi":"10.1097/CU9.0000000000000329","DOIUrl":"10.1097/CU9.0000000000000329","url":null,"abstract":"","PeriodicalId":39147,"journal":{"name":"Current Urology","volume":"20 2","pages":"125-126"},"PeriodicalIF":1.3,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12885692/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146158674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Revealing the function and mechanism of piRNA-related genes in bladder cancer through single-cell sequencing and methylation analyses and construction of prognostic features based on consensus clustering.","authors":"Xun Sun, Dongdong Jia, Xiaoyun Song, Ying Jiang, Fei Wu, Hao Ning, Jiaju Lyu","doi":"10.1097/CU9.0000000000000306","DOIUrl":"10.1097/CU9.0000000000000306","url":null,"abstract":"<p><strong>Background: </strong>This study aimed to explore the functions and potential mechanisms of PIWI-interacting RNA-related genes (piRPGs) in bladder cancer (BC) development and to identify potential prognostic genes.</p><p><strong>Methods: </strong>This study used differential analysis and machine learning techniques to identify the differentially expressed piRPGs in BC. Consensus clustering was performed on The Cancer Genome Atlas-Urothelial Bladder Carcinoma dataset, and univariate and multivariate analyses were conducted to construct a BC prognostic model consisting of 3 piRPGs. Kaplan-Meier survival curves were used for survival analysis. Quantitative polymerase chain reaction was performed to validate the expression levels of piRPGs in BC cells and tissues. The functional roles and potential mechanisms of piRPGs in BC were investigated via single-cell sequencing and differentially methylated position sequencing. The DSigDB and CellMiner databases were used to screen for small-molecule drugs associated with piRPGs.</p><p><strong>Results: </strong>This study identified 6 piRPGs that were significantly associated with BC: MAPK13, INHBA, LAMB2, DDX3X, TARBP2, and CDK2. A prognostic model comprising MAPK13, INHBA, and LAMB2 was constructed using consensus clustering technology. Kaplan-Meier curves demonstrated significantly prolonged survival in cluster 2 compared with cluster 1 (<i>p</i> < 0.01), validating the effectiveness of the prognostic model. Single-cell sequencing confirmed that MAPK13 expression was significantly upregulated in bladder tissues (<i>p</i> < 0.001). Methylation site sequencing and methylation-specific polymerase chain reaction revealed significantly decreased methylation levels of INHBA and MAPK13 in BC tissues, which were inversely correlated with their expression levels.</p><p><strong>Conclusions: </strong>This study effectively developed a 3-gene prognostic signature comprising MAPK13, INHBA, and LAMB2 using consensus clustering and multifactorial logistic regression. In addition, the functional roles and intrinsic mechanisms of piRPGs in bladder carcinogenesis were comprehensively explored using single-cell sequencing, methylation sequencing, and functional enrichment analysis.</p>","PeriodicalId":39147,"journal":{"name":"Current Urology","volume":"20 2","pages":"101-116"},"PeriodicalIF":1.3,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12885747/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146158726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Current UrologyPub Date : 2026-03-01Epub Date: 2025-12-05DOI: 10.1097/CU9.0000000000000318
Benjamin Koff, Jamie Kim, Robert White, Tal Cohen
{"title":"Microplastics crossing the blood-testis barrier: A call to action for urological research.","authors":"Benjamin Koff, Jamie Kim, Robert White, Tal Cohen","doi":"10.1097/CU9.0000000000000318","DOIUrl":"10.1097/CU9.0000000000000318","url":null,"abstract":"","PeriodicalId":39147,"journal":{"name":"Current Urology","volume":"20 2","pages":"89-90"},"PeriodicalIF":1.3,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12885661/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146158721","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}